Merck's Lead Cancer Drug Meets Primary Goal In Certain Type Of Lung Cancer Patients
Portfolio Pulse from Vandana Singh
Merck & Co Inc reported positive topline data from the Phase 3 KEYNOTE-671 trial investigating Keytruda, its lead cancer drug, as a treatment for certain types of non-small cell lung cancer. The study met its dual primary endpoint of overall survival. Full results will be presented at the European Society for Medical Oncology Congress 2023. The FDA has accepted Merck's new supplemental marketing application with a target action date of October 16, 2023.
October 10, 2023 | 4:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merck's lead cancer drug Keytruda has shown positive results in a Phase 3 trial, potentially leading to increased demand and positive impact on the company's stock.
Positive clinical trial results often lead to increased demand for a company's product, which can positively impact the company's stock. In this case, the positive results for Merck's Keytruda could lead to increased demand for the drug, potentially boosting the company's revenues and positively impacting its stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100